Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 317.1% in April

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 105,100 shares, an increase of 317.1% from the March 31st total of 25,200 shares. Based on an average trading volume of 497,100 shares, the short-interest ratio is currently 0.2 days. Currently, 25.0% of the shares of the stock are short sold.

Allarity Therapeutics Stock Performance

Allarity Therapeutics stock traded up $0.06 during midday trading on Thursday, reaching $1.43. The company’s stock had a trading volume of 221,894 shares, compared to its average volume of 407,973. Allarity Therapeutics has a 52 week low of $1.27 and a 52 week high of $415.92. The business has a 50-day moving average price of $5.84 and a 200-day moving average price of $8.94.

Institutional Trading of Allarity Therapeutics

An institutional investor recently bought a new position in Allarity Therapeutics stock. Armistice Capital LLC acquired a new position in Allarity Therapeutics, Inc. (NASDAQ:ALLR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 261,000 shares of the company’s stock, valued at approximately $195,000. Armistice Capital LLC owned 9.56% of Allarity Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.